<DOC>
	<DOCNO>NCT00946192</DOCNO>
	<brief_summary>One aim study determine change body composition hormone differentiate athlete stop get period versus continue get period non-athletes . The second aim study determine whether transdermal oral estrogen ( versus estrogen ) effective increase bone density improve bone microarchitecture adolescent athletes get period thus estrogen deficient . The investigator hypothesize transdermal estrogen effective oral estrogen estrogen improve bone health amenorrheic adolescent athlete .</brief_summary>
	<brief_title>Fat Mediated Modulation Reproductive Endocrine Function Young Athletes</brief_title>
	<detailed_description>As many 25 % adolescent young adult endurance athlete develop amenorrhea , factor cause amenorrhea occur , , athletes well characterize . Recent data indicate critical importance negative energy balance state leptin regulate Hypothalamic-pituitary-gonadal ( H-P-G ) axis . However , factor completely account alteration axis , contribute factor unclear . Our preliminary data indicate importance low fat mass fat relate hormone mediate hypogonadism young athlete . This study confirm data determine whether low fat mass alter level adipokines , leptin adiponectin , hormone regulate fat mass , ghrelin peptide YY ( PYY ) , determine alteration LH pulsatility . A concern impact amenorrhea athlete low bone mineral density ( BMD ) . Preliminary data indicate lower BMD adolescent athlete amenorrhea ( AA ) compare eumenorrheic athlete ( EA ) non-athletic control . The high prevalence AA adolescents particularly concerning , population potentially great risk actively accrue bone . Of importance , bone microarchitecture , good predictor bone strength BMD , study AA . Because pubertal increase estrogen integral optimize peak bone mass , AA characterize hypoestrogenism , randomize study transdermal estrogen versus oral estrogen estrogen also examine whether estrogen replacement increase BMD improve bone microarchitecture adolescent AA 14-21 year old . EA sedentary control follow without intervention period . Despite prevalent practice prescribe oral contraceptive AA , paucity data regard benefit intervention teenager . Because transdermal estrogen , unlike oral estrogen , suppress IGF-1 , important bone anabolic factor , expect effect transdermal estrogen exceed oral estrogen therapy . In addition , preliminary data indicate low fat mass alteration fat relate hormone may contribute decrease bone accrual rate athlete , confirm study . To summarize , good understand pathophysiology reproductive dysfunction critical develop therapeutic strategy normalize reproductive axis bone accrual , question study aim answer .</detailed_description>
	<mesh_term>Amenorrhea</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Females 1421 year old Note : Our pilot data reassure young woman 1825 year old hypothalamic amenorrhea adversely affect estrogen use . In fact , prospective study , beneficial effect observe young woman 1825 year old use oral estrogen , 1418 year old adolescent girl use transdermal estrogen . We therefore feel include girl 1421 year age range hazardous bone health . In fact , give lack data age group , important study young woman teenager rather extrapolate data study adult young population . Hormone dynamic differ teenager compare adult , bone mass accrual even dependent estrogen IGF1 young old woman already achieve peak bone mass . Bone age ( BA ) &gt; 15 year Note : 99 % adult height achieve BA 15 year , thus estrogen replacement result stunt height potential age . Although could choose include girl BA &gt; 14 study , limit girl BA &gt; 15 year . This 2 % growth potential persists BA 14 year , versus 1 % BA 15 year ( ~0.6 '' potential height ( 130 ) ) . Thus , avoid potential stunting growth potential estrogen replacement , choose include girl BA &gt; 15 year . BMI 10th90th percentile age . Amenorrhea ( AA ) : absence menses &gt; three month ( 74 ) within period oligomenorrhea ( cycle length &gt; six week ) &gt; six month , absence menarche &gt; 16 year . Eumenorrhea ( EA control ) : &gt; nine menses ( cycle length 2135 day ) precede year . Nonathlete healthy control eligible weight bearing exercise activity less two hour week participate organize team sport . Endurance athlete Note : severity low BMD menstrual dysfunction differ kind exercise activity . For example , runners high prevalence menstrual irregularity swimmer cyclist ( 131 ) . By limit enrollment endurance athlete , eliminate variability type activity . Endurance training define &gt; 4 h aerobic weightbearing training leg specific endurance training weekly , &gt; 20 mile run weekly period &gt; 6 month last year . Other condition may affect bone metabolism</criteria>
	<gender>Female</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Amenorrhea</keyword>
	<keyword>Adolescent</keyword>
	<keyword>Endurance</keyword>
	<keyword>Athletes</keyword>
	<keyword>Females</keyword>
	<keyword>Osteopenia</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Estrogen</keyword>
</DOC>